| Literature DB >> 36062199 |
Mohammed S Aleissa1, Mohammed Al-Zharani1, Md Saquib Hasnain2, Saad Alkahtani3.
Abstract
Coronavirus (covid-19) infection is considered to be deadliest ever pandemic experienced by the human being. It has very badly affected the socio-economic health of human and stuck the scientific community to think and rethink about its complete eradication. But due to no effective treatment or unavailability of vaccine the health professional could not show any significant improvement to control the pandemic. The situation needs newer molecule, vaccine or effective treatment to control covid-19 infection. Different target in viruses has been explored and proteases enzymes were found to be therapeutically effective target for the design of potential anti-covid-19 molecule as it plays the vital role in viral replication and assembly. Structure-based drug design was employed to discover the small molecule of anti-covid-19. Here we considered the small library of naturally occurring polyphenolic compounds and molecular docking, Molecular dynamics (MD) simulations, free binding energy calculation and in-silico ADME calculations to identify the newer HITs. Based upon their score the two molecules were identified as promising candidate. The docking scores were found to be -7.643 and -7.065 for the HIT1 and HIT-2 respectively. In MD simulations study the RMSD values were found to be 4.3 Å & 4.9 Å respectively. To validate these results MM-GBSA was performed and their binding free energies were computationally determined. The prime energy values of identified HITs (-13412.45 & -13441.8 kJ/mole) were found to be very close proximity to reference molecule (-13493.05 kJ/mole). Then in-silico ADME calculations were performed to calculate the drug likeliness identified HITs. BY considering all the values comparative to reference molecule and obtained in-silico pharmacokinetic properties of identified HITs we can suggest that HIT-1 and HIT-2 would be the most promising molecules that can inhibit the main protease enzyme of covid-19. These two molecules would become the potential drug candidate for the treatment of covid-19 infections.Entities:
Keywords: Covid-19; HIT; MD simulation; Phenolic compounds; Protease inhibitor
Year: 2022 PMID: 36062199 PMCID: PMC9428119 DOI: 10.1016/j.jksus.2022.102283
Source DB: PubMed Journal: J King Saud Univ Sci ISSN: 1018-3647
Figure 1A & B: 3D view of 6LU7 protein analysed for Ramachandran plot, green colour favoured region, cyan colour allowed region and red colour disallowed region. C; RMSD deviation present between each amino acid residues.
List of top identifed molecules with their docking scores and different types of interactions with active site residues (PDB id: 6LU7)
| Molecule | Molecule structure | Docking score | Type of interactions | Active site residues |
|---|---|---|---|---|
| Reference molecule | Polar H-Bond | Gly143 | ||
| Hydrophobic | Met165; Met49; Cys145; Leu27 | |||
| Polar interactions | Thr25, Thr26; Ser144; Asn142; His164; His41; Gln189 | |||
| π-πstacking | His41 | |||
| HIT-1 | -7.643 | Polar H-Bond | Thr26; Ser46; Leu141; Gln166; Gln189; Thr190 | |
| Hydrophobic | Met49; Ala191; Leu141; Met165; Pro168; Cys145; Leu27 | |||
| Polar interactions | ||||
| HIT-2 | -7.065 | Polar H-Bond | His41; Thr26 | |
| Hydrophobic | Leu27; Cys44; Val42; Tyr54 | |||
| Polar interactions | Thr26; Thr25; His41; Asn142; Gln189 | |||
| HIT-3 | -6.738 | Polar H-Bond | Thr26; Gly143; His164; Gln189 | |
| Hydrophobic | Leu141; Cyc145; Leu27; Met49; Ala191; Pro168; Leu167; Met165 | |||
| Polar interactions | Asn142; Ser144; Thr26; Thr25; Gln189; Thr190; Gln192; His164; His163; His41 | |||
| HIT-4 | -6.685 | Polar H-Bond | Thr26; Glu166 | |
| Hydrophobic | Leu141; Cyc145; Leu27; Tyr54; Pro52; Met49; Met165; Cys44 | |||
| Polar interactions | His163; His164; Gln189; His41; Thr25; Thr26; Ser144, Asn142 | |||
| HIT-5 | -6.662 | Polar H-Bond | Thr26; Gln189; Glu166; Asn142; Gly143 | |
| Hydrophobic | Met49; Pro52; Tyr54; Met165; Leu27; Cys44; Leu141; Cys145 | |||
| Polar interactions | Glu189; Hs164; His163; Asn142; Ser144; Asn119; His41; Thr45; Ser46; Thr26; Thr25; Thr24 | |||
| HIT-6 | -6.638 | Polar H-Bond | Asn142; His164; Glu166; Gly138; Gly170 | |
| Hydrophobic | Met49; Cys145; Met165; Leu141; Phe140; Val171 | |||
| Polar interactions | Hie172; Ser139; Asn142; His164; His163; Gln189; His41 | |||
| HIT-7 | -6.619 | Polar H-Bond | Thr26; Gly143; Ap187 | |
| Hydrophobic | Leu27; Tyr54; Val42; Pro52; Cys44; Met49; Met165 | |||
| Polar interactions | Asn142; Thr25; Thr26; His41; Gln189 | |||
| HIT-8 | -6.603 | Polar H-Bond | Thr26; His164; | |
| Hydrophobic | Leu27; Cys145; Met165; Leu167; Tyr54; Pro168; Val186; Met49 | |||
| Polar interactions |
A summary of various values obtained after the free binding energies calculation
| Reference | -13493.05 | -101.59 | -10026.37 | |
| HIT-1 Corilagin | -13412.45 | -100.09 | -9936.31 | |
| HIT-2Oxyresveratrol | -13441.8 | -100.47 | -9958.57 | |
| HIT-3Hexahydrocurcumin | -13435.92 | -102.1 | -9694.31 |
In-silico pharmacokinetic profiling of reference molecule and identified HITs
| Reference | HIT-1 Corilagin | HIT-2Oxyresveratrol | HIT- 3 Hexahydrocurcumin | ||
|---|---|---|---|---|---|
| HB Donor | 0 | 11 | 4 | 2 | |
| HB Acceptor | 3.5 | 17.85 | 3 | 5.7 | |
| LogPO/W | 4.285 | -3.052 | 1.296 | 3.605 | |
| logBB | -0.150 | -5.83 | -1.773 | -2.054 | |
| #Metabolism | 11 | 4 | 9 | ||
| % Human oral Absorption | 100 | 40.346 | 70.575 | 90.978 | |
| PSA | 56.725 | 325.167 | 88.358 | 105.478 | |
| Ro5 Violation | 0 | 3 | 0 | 0 | |
| Ro3 Violation | 0 | 0 | 0 | 0 | |
| Molecular Weight | 334.39 | 634.46 | 244.246 | 374.433 |
Figure 2Methodology adopted for the design and discovery of small molecule inhibitors against the COVID main protease.
Figure 33D overlay of identified top HITs from 1-8 at the active site of COVID main protease enzyme. Yellow dash line indicate the polar H bonding interactions between the ligand atom and active site residues whereas green line displayed the hydrophobic interactions
Figure 4Structural changes (RMSD) over the entire trajectory run of 50ns upon binding of ligands (1a: HIT1; 2a: HIT2) and Fluctuations of residues (RMSF) at the active site of on binding of ligands (1a: HIT1; 2a: HIT2) Corona virus (PDB id: 6LU7).
Figure 5Protein ligands contacts (1a: HIT1; 2a: HIT2) and protein ligand contacts histogram (1b: HIT1; 2b: HIT2) of identified HITs at the active site of COVID Mpro enzyme over the entire run of 50ns.
Figure 6Depiction of different metabolic site in identified HIT-1 and HIT-2, predicted by SMARTCyp.